Anke Baum

BIBW2992, an irreversible EGFR/HER2 inhibitor highly effective in preclinical lung cancer models

D Li, Lauren Ambrogio, Takeshi Shimamura et al. · Oncogene · 2008 · 1.4K citations · Full text

Systems Biology, Medicine, Bronchial Neoplasm +8

BI 2536, a Potent and Selective Inhibitor of Polo-like Kinase 1, Inhibits Tumor Growth In Vivo

Martin Steegmaier, Matthias Hoffmann, Anke Baum et al. · Current Biology · 2007 · 839 citations · Full text

Tumor Biology, Bi 2536, Medicine +9

BI 6727, A Polo-like Kinase Inhibitor with Improved Pharmacokinetic Profile and Broad Antitumor Activity

Dorothea Rudolph, Martin Steegmaier, Matthias Hoffmann et al. · Clinical Cancer Research · 2009 · 388 citations · Full text

Start Selective and Rigidify: The Discovery Path toward a Next Generation of EGFR Tyrosine Kinase Inhibitors

Harald Engelhardt, Dietrich Böse, Mark Petronczki et al. · Journal of Medicinal Chemistry · 2019 · 139 citations · Full text

A novel Fc-engineered monoclonal antibody to CD37 with enhanced ADCC and high proapoptotic activity for treatment of B-cell malignancies

Karl‐Heinz Heider, Kerstin Kiefer, Thorsten Zenz et al. · Blood · 2011 · 103 citations · Full text